Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $9
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Larry Biegelsen maintains RxSight (NASDAQ:RXST) with a Equal-Weight and lowers the price target from $11 to $9.
Wells Fargo analyst Larry Biegelsen maintains RxSight (NASDAQ:RXST) with a Equal-Weight and lowers the price target from $11 to $9.